Global Leader in Oral Delivery of Therapeutic Proteins
We are a clinical stage, global company, focused on high unmet clinical needs where oral delivery of a protein therapy can significantly improve the standard of care
LATEST NEWS
Press Releases
- August 20, 2024
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
- May 15, 2024
Phase 2 Published in JBMR
- August 20, 2024
Entera Bio Featured in BioTeusdays
- May 3, 2023
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
Events
- August 20, 2024
Entera Bio to Participate in Upcoming Investor and Scientific Conferences – HCW, ASBMR, and Evercore
- September 9, 2022
Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact
Therapeutic Areas
Osteoporosis
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.
ABOUT US
Entera is Daring Courageous Fierce
We are developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Our goal is for our small, oral protein tablets to change treatment outcomes for patients globally.
- May 15, 2024
